Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
This research study is studying a drug as a possible treatment for Monoclonal Gammopathy of Unknown Significance (MGUS) or Smoldering Multiple Myeloma (SMM).
The drug involved in this study is:
A Phase II Study of the CD38 Antibody Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
- ClinicalTrials.gov Identifier: NCT03236428
- Protocol Number: 17-212
- Principal Investigator: Jacalyn Rosenblatt
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required